Interleukin-12: A Recently Discovered Cytokine with Potential for Enhancing Cell-Mediated Immune Responses to Tumors

This publication has 22 references indexed in Scilit:

• Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients.
  The Journal of Experimental Medicine, 1992
• Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.
  The Journal of Experimental Medicine, 1992
• Sequence similarity between NKSF and the IL-6/G-CSF family
  Immunology Today, 1992
• Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4
  Science, 1991
• Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor
  Cell, 1991
• Molecular cloning and expression of an IL-6 signal transducer, gp130
  Cell, 1990
• Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
  The Journal of Experimental Medicine, 1989
• Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.
  The Journal of Experimental Medicine, 1989
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985